“The manager initiated a position in this long-followed company after strong first-quarter results and an upgraded outlook. The business is experiencing rapid margin improvement driven by the launch of Asceniv for primary immunodeficiency.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
